| | OCTOBER 20269PHARMA PRICING UNDER SIEGE: KEY INTERVENTIONS OF THE MONTHLUPIN UNVEILS FORMOFLO-G MDI TO EXPAND COPD TREATMENT OPTIONSNOVO WEGOVY PILL: 4.1 PERCENT WEIGHT LOSS AFTER INJECTION SWITCHINDIA EXPANDS EARLY DETECTION WITH 420M PRIMARY CARE SCREENINGSSANOFI ADDS 4 LONG-ACTING ANTIBODIES FOR USD 1BNPharma pricing comes under siege this month as high-profile drug price caps and regulatory interventions intensify across India and beyond. The Supreme Court flags steep markups on cancer medicines and presses for a uniform 16 percent margin on all medicines.State regulators in Karnataka and Maharashtra expose unfair margins on medical devices and hospital consumables, while the NPPA faces industry pushback. Globally, Sun Pharma joins Most Favored Nation deals aimed at cutting US retail drug costs. POLupin Limited has launched Formoflo-G MDI, a fixed-dose triple-combination metered-dose inhaler for COPD treatment in India. The launch, announced on October 6, 2026, expands the company's respiratory care portfolio and adds another treatment option for patients managing chronic obstructive pulmonary disease (COPD).The Formoflo-G MDI combines three active ingredients: Glycopyrronium Bromide, Formoterol Fumarate, and Fluticasone Propionate. The inhaler is designed for the long-term management of moderate to severe COPD and is available as a twice-daily, single-strength fixed-dose combination. POWegovy pill users who switched from injectable obesity treatments lost an average 4.1 percent of their body weight over three months, according to new real-world data from Novo Nordisk's OCTANE study. The analysis, presented at the European Association for the Study of Diabetes meeting in Milan, involved 194 adults who moved from injectable semaglutide or tirzepatide to oral semaglutide.The findings add a different dimension to the expanding oral obesity drug market: rather than viewing pills only as an alternative to injections, the data raises the question of whether oral semaglutide could provide a treatment-continuity pathway for patients already using injectable GLP-1 therapies. POIndia powers primary care with an extraordinary scale of early detection. Union Health Minister J.P. Nadda announces that more than 420 million screenings for hypertension and 420 million for diabetes have already taken place. The nationwide network of Ayushman Arogya Mandirs has also completed 360 million oral cancer screenings, 170 million breast cancer screenings, and 90 million cervical cancer screenings.These 1.86 lakh centers now stand as the backbone of population-based screening for people aged 30 and above. The numbers reveal both a focused push for women's cancer equity and a striking level of last-mile productivity that few primary-care systems worldwide can match. POLong-acting immunology antibodies are becoming an important part of Sanofi and Regeneron's strategy to extend their work in type 2 inflammation beyond Dupixent. The companies have expanded their more than 20-year collaboration by adding four next-generation antibodies, with Sanofi paying Regeneron USD 1 billion upfront and potentially another USD 7 billion in milestones.however, is whether this molecular switch can be converted into a controllable therapeutic platform. POThe agreement includes REGN20423, a Phase 1 IL-13 antibody, alongside an IL-4xIL-13 bispecific and two other long-acting preclinical antibodies. With more than 1.5 million people receiving Dupixent across nine indications, the expansion provides a closer look at how the partners are developing the next generation of immunology therapies. PO
< Page 8 | Page 10 >